Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.83 USD | +11.06% | +4.40% | +552.50% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+552.50% | 19.76M | - | ||
+16.80% | 8.33B | D+ | ||
+3.59% | 7.73B | C- | ||
+15.02% | 6.83B | - | ||
-6.75% | 3.78B | D | ||
-3.74% | 3.76B | B- | ||
+4.41% | 1.45B | - | - | |
+20.28% | 1.05B | - | ||
-13.96% | 882M | C+ | ||
-15.85% | 778M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZIVO Stock
- Ratings ZIVO Bioscience, Inc.